Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minagawa, Y.
Right arrow Articles by Terakawa, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minagawa, Y.
Right arrow Articles by Terakawa, N.

Annals of Surgical Oncology, Vol 5, Issue 6 539-543, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Radical surgery following neoadjuvant chemotherapy for patients with stage IIIB cervical cancer

Y. Minagawa, J. Kigawa, T. Irie, M. Okada, Y. Kanamori and N. Terakawa
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Japan.

BACKGROUND: We conducted a phase II trial of radical surgery following neoadjuvant chemotherapy in patients with stage IIIB cervical cancer. METHODS: A total of 26 patients with stage IIIB cervical cancer were entered in this study. Patients were treated with a chemotherapeutic regimen consisting of intraarterial infusion of cisplatin and intravenous infusion of other anticancer agents, to a maximum of 3 courses. If the results of the evaluation indicated that surgery was feasible, radical surgery, including complete removal of pelvic vessels, partial resection of adjacent organs, and pelvic and paraaortic lymphadenectomy, was performed. Patients whose tumors showed no response received radiotherapy. We evaluated operability, survival rate, toxicities, and complications. Additionally, we examined prognostic variables by multivariate analysis in the patients treated by radical surgery. RESULTS: Eighteen patients (69.2%) underwent radical surgery. The remaining eight patients received radiation therapy. The 3-year disease-free survival rate was 72.2% in patients who received surgery and 25.0% in those who received radiotherapy. Multivariate analysis did not show any independent prognostic factors in the patients who underwent surgery. CONCLUSION: Radical surgery following neoadjuvant chemotherapy may be feasible in two thirds of patients with stage IIIB cervical cancer; therefore, phase III trials can be recommended.


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, L. Cetina, L. Rivera, I. Mariscal, G. Montalvo, E. Gomez, J. de la Garza, G. Chanona, et al.
A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation
Ann. Onc., August 1, 2003; 14(8): 1278 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Sultana, J. Kigawa, Y. Kanamori, H. Itamochi, T. Oishi, S. Sato, S. Kamazawa, M. Ohwada, M. Suzuki, and N. Terakawa
Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer
Ann. Onc., February 1, 2003; 14(2): 214 - 219.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, A. Mohar, L. Rivera, A. Mota, R. Guadarrama, G. Chanona, and J. de la Garza
Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies
Ann. Onc., August 1, 2002; 13(8): 1212 - 1219.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.